Open an account

Rani Therapeutics Holdings

RANI · NASDAQ

$0.6528+$0.0025 (+0.38%)TodayMarket closed ·
Prev close $0.6503

RANI analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy4
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 7 analysts

Average $7.34 (+1025.0% upside)

Low
$5.05
Now
$0.6528
High
$11.55

Upgrades and downgrades

The latest rating actions, newest first

RANI analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Aug 21, 2026MaintainsBuy
Chardan CapitalAug 18, 2026InitiatesBuy
Canaccord GenuityMay 20, 2026MaintainsBuy
Canaccord GenuityApr 1, 2026MaintainsBuy
HC Wainwright & Co.Mar 27, 2026MaintainsBuy
HC Wainwright & Co.Jan 9, 2026MaintainsBuy
HC Wainwright & Co.Oct 21, 2025InitiatesBuy
Maxim GroupOct 20, 2025MaintainsBuy

The case for and against

Updated Oct 14, 2026

Bull case

Rani Therapeutics Hldgs is attractive because its RaniPill HC platform has already produced human bioavailability comparable to, and in RT-114’s case above, subcutaneous dosing, which materially de-risks the core technology and supports the view that oral delivery can replace injections across multiple biologics. The investment case is strengthened by third-party validation from Chugai and the PegBio partnership, which create additional monetization paths beyond RT-114 and could expand into up to five additional targets, while also showing clear pharma appetite for the platform. Fundamentally, the company appears financially steadier after 2Q26, with EPS of $(0.04), R&D expense of $5.0M, $1.7M of contract revenue, and $53.4M in cash and marketable securities, giving it runway into 2027 and supporting execution toward YE26 and 2027 catalysts.

Bear case

Rani Therapeutics Hldgs is viewed negatively because its core investment case still hinges on an unproven human pharmacodynamic link, even though it has built a compelling human PK dataset. The first major test is RT-114 Phase 1b, but the company’s history of pipeline reprioritizations, tighter capital position, and underfollowed microcap status with limited specialist coverage have already dampened investor conviction. Even if data improve, execution remains vulnerable to repeat-dose uncertainty, partner dependence, generic or biosimilar competition, and regulatory risk tied to the IDE and device Master File path.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.